Gene Therapy for Canavan's Disease Takes a Step Forward

Molecular Therapy

Volumn 21, Issue 3, 2013, Pages 505-506

  Ahmed, Seemin S ^a   Gao, Guangping ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTOACYLASE; PARVOVIRUS VECTOR; PLASMID DNA;

ABSENCE OF SIDE EFFECTS; ASPARTOACYLASE GENE; CANAVAN DISEASE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; GENE; GENETIC TRANSDUCTION; HUMAN; MOTOR PERFORMANCE; NONHUMAN; NOTE; QUALITY OF LIFE; RARE DISEASE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 84875124476     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.25     Document Type: Note

References (13)

1. Matalon, R, Michals, K, Sebesta, D, Deanching, M, Gashkoff, P and Casanova, J (1988). Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. Am J Med Genet 29: 463-471.
2. Stenson, PD, Ball, EV, Mort, M, Phillips, AD, Shiel, JA, Thomas, NS et al. (2003). Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat 21: 577-581.
3. Matalon, R, Kaul, R, Gao, GP, Michals, K, Gray, RG, Bennett-Briton, S et al. (1995). Prenatal diagnosis for Canavan disease: the use of DNA markers. J Inherit Metab Dis 18: 215-217.
4. Kaul, R, Gao, GP, Balamurugan, K and Matalon, R (1993). Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease. Nat Genet 5: 118-123.
5. Matalon, R and Michals-Matalon, K (1998). Molecular basis of Canavan disease. Eur J Paediatr Neurol 2: 69-76.
6. Leone, P, Janson, CG, Bilaniuk, L, Wang, Z, Sorgi, F, Huang, L et al. (2000). Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease. Ann Neurol 48: 27-38.
7. Janson, C, McPhee, S, Bilaniuk, L, Haselgrove, J, Testaiuti, M, Freese, A et al. (2002). Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum Gene Ther 13: 1391-1412.
8. Leone, P, Shera, D, McPhee, SW, Francis, JS, Kolodny, EH, Bilaniuk, LT et al. (2012). Long-term follow-up after gene therapy for Canavan disease. Sci Transl Med 4: 165ra163.
9. Zhang, H, Yang, B, Mu, X, Ahmed, SS, Su, Q, He, R et al. (2011). Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol Ther 19: 1440-1448.
10. Yang, B, Cao, C, Zhang, H, Su, Q, Ahmed, SS, Zhong, L et al. (2012). Intravascular delivery of rAAVrh.8 generates widespread transduction of neuronal and glial cell types in adult mouse central nervous system. Presented at the 15th annual meeting of the American Society of Gene and Cell Therapy, Philadelphia, PA, 15-19 May 2012. Mol Ther 20 (suppl.): S203.
11. Foust, KD, Nurre, E, Montgomery, CL, Hernandez, A, Chan, CM and Kaspar, BK (2009). Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 27: 59-65.
12. Klugmann, M, Leichtlein, CB, Symes, CW, Serikawa, T, Young, D and During, MJ (2005). Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease. Mol Ther 11: 745-753.
13. Foust, KD, Wang, X, McGovern, VL, Braun, L, Bevan, AK, Haidet, AM et al. (2010). Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 28: 271-274.